Several other analysts also recently issued reports on FCSC. Zacks Investment Research downgraded shares of Fibrocell Science from a strong-buy rating to a hold rating in a report on Tuesday, January 15th. HC Wainwright reissued a buy rating and issued a $22.00 price target on shares of Fibrocell Science in a report on Thursday, March 28th.
Shares of FCSC traded up $0.08 during mid-day trading on Friday, hitting $1.99. 102,300 shares of the company’s stock were exchanged, compared to its average volume of 692,324. Fibrocell Science has a twelve month low of $1.45 and a twelve month high of $5.17. The firm has a market cap of $20.12 million, a price-to-earnings ratio of -1.37 and a beta of 1.66.
A number of institutional investors have recently modified their holdings of FCSC. Renaissance Technologies LLC grew its holdings in shares of Fibrocell Science by 126.7% during the third quarter. Renaissance Technologies LLC now owns 367,941 shares of the company’s stock valued at $868,000 after buying an additional 205,660 shares in the last quarter. Virtu Financial LLC grew its holdings in shares of Fibrocell Science by 90.7% during the first quarter. Virtu Financial LLC now owns 39,864 shares of the company’s stock valued at $77,000 after buying an additional 18,958 shares in the last quarter. Apis Capital Advisors LLC purchased a new position in shares of Fibrocell Science during the first quarter valued at $48,000. Finally, Morgan Stanley grew its holdings in shares of Fibrocell Science by 92.6% during the first quarter. Morgan Stanley now owns 52,900 shares of the company’s stock valued at $102,000 after buying an additional 25,440 shares in the last quarter. 28.20% of the stock is owned by hedge funds and other institutional investors.
About Fibrocell Science
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Featured Story: How to Profit and Limit Losses With Stop Orders
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.